American Journal of Physiology-Cell Physiology · 2014 · 80 citations · 46 references
MedicineOncologyPharmacologyApoptosisChemotherapyMolecular OncologyApoptosis ResistanceCellular Drug EffluxChemotherapy ResistanceOncology PharmacologyOvarian Cancer PharmacotherapyPharmacodynamics Of Anticancer DrugsApoptotic EvasionCellular Drug AccumulationIntracellular Drug AccumulationOvarian Cancer ChemotherapyPhospholipase A2 InhibitionPhospholipase A2 PathwayPlatinum SensitivityZafirlukast Therapy
Cisplatin resistance is a major challenge in the treatment of cancer and develops through reduced drug accumulation and an increased ability to avoid drug-induced cell damage, cell shrinkage, and hence initiation of apoptosis. Uptake and release of the semiessential amino acid taurine contribute to cell volume homeostasis, and taurine has been reported to have antiapoptotic effects. Here we find that volume-sensitive taurine release in cisplatin-sensitive [wild-type (WT)] human ovarian cancer A2780 cells is reduced in the presence of the phospholipase A2 inhibitor bromenol lactone, the 5-lipoxygenase (5-LO) inhibitor ETH 615-139, and the cysteine leukotriene receptor 1 (CysLT1) antagonist zafirlukast and impaired by the anion channel blocker DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonate). Comparing WT and cisplatin-resistant (RES) A2780 cells we also find that evasion of cisplatin-induced cell death in RES A2780 cells correlates with an increased accumulation of taurine, due to an increased taurine uptake and a concomitant impairment of the volume-sensitive taurine release pathway, as well an inability to reduce cell volume after osmotic cell swelling. Downregulation of volume-sensitive taurine release in RES A2780 cells correlates with reduced expression of the leucine-rich repeat-containing protein 8A (LRRC8A). Furthermore, acute (18 h) exposure to cisplatin (5-10 μM) increases taurine release and LRRC8A expression in WT A2780 cells whereas cisplatin has no effect on LRRC8A expression in RES A2780 cells. It is suggested that shift in LRRC8A activity can be used as biomarker for apoptotic progress and acquirement of drug resistance.
46
Nod1, an Apaf-1-like Activator of Caspase-9 and Nuclear Factor-κB
Naohiro Inohara, Takeyoshi Koseki, Luis del Peso et al. · Journal of Biological Chemistry · 1999 · 731 citations · Full text
SWELL1, a Plasma Membrane Protein, Is an Essential Component of Volume-Regulated Anion Channel
Zhaozhu Qiu, Adrienne E. Dubin, Jayanti Mathur et al. · Cell · 2014 · 579 citations · Full text
Pannexin-1 Is Required for ATP Release during Apoptosis but Not for Inflammasome Activation
Yan Qu, Shahram Misaghi, Kim Newton et al. · The Journal of Immunology · 2011 · 356 citations · Full text